Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 33,088 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Recruiting Phase 3 Interventional

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant tablet, Placebo tablet
Drug · Other
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome

NCT00107809
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 16 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
60
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Fatty Acid Supplementation in Children With ASD

NCT03550209
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
LCPUFA Oil Supplement, Canola Oil Placebo
Drug · Dietary Supplement
Lead sponsor
Sarah Keim
Other
Eligibility
2 Years to 6 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma

NCT04108377
View directory record Official record
Conditions
Asthma
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

NCT01484275
View directory record Official record
Conditions
High-risk Smoldering Multiple Myeloma
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

NCT00481975
View directory record Official record
Conditions
Obesity, Eating Disorders
Interventions
rimonabant (SR141716)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224

NCT04932512
View directory record Official record
Conditions
Steatohepatitis, Nonalcoholic
Interventions
ION224, Placebo
Drug · Other
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
50
States / cities
Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

NCT03173781
View directory record Official record
Conditions
Parkinson's Disease
Interventions
droxidopa, Placebo
Drug
Lead sponsor
Colorado Springs Neurological Associates
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 23, 2026, 4:46 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Tirzepatide, Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
141
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

Broccoli Sprout Extract in Treating Women Who Have Had a Mammogram and Breast Biopsy

NCT00843167
View directory record Official record
Conditions
Breast Cancer, Precancerous Condition
Interventions
broccoli sprout extract, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

NCT00814307
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
31
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

NCT01384292
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Casa Grande, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain

NCT03263611
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Placebo, AMG0103
Drug
Lead sponsor
AnGes, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Acute Grape Seed Extract Supplementation on Muscle Metaboreflex in Healthy Young Individuals

NCT05945771
View directory record Official record
Conditions
Dietary Supplementation
Interventions
Grape seed extract
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

NCT01550471
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris, Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 15 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Green Tree, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

NCT05282771
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 2 Interventional Results available

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT01666444
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
136
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of Peppermint Oil During Screening Colonoscopy to Improve Visibility

NCT03286764
View directory record Official record
Conditions
Enhancement of the ADR During Colonoscopy
Interventions
Peppermint Oil, Distilled water
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects

NCT01540864
View directory record Official record
Conditions
Obesity, Overweight
Interventions
HPP404, Placebo
Drug
Lead sponsor
High Point Pharmaceuticals, LLC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Augusta, Georgia • Valparaiso, Indiana • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Not applicable Interventional

Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)

NCT03183609
View directory record Official record
Conditions
Schizophrenia, Gluten Sensitivity, Schizo Affective Disorder
Interventions
Gluten Flour in Protein Shake, Rice Flour in Protein Shake
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 23, 2026, 4:46 AM EDT
Completed Phase 4 Interventional

Continuous Positive Airway Pressure (CPAP) Promotion And Prognosis - the Army Sleep Apnea Program (ASAP)

NCT00612157
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Eszopiclone, Placebo control
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2009 · Synced Oct 23, 2026, 4:46 AM EDT
Suspended Not applicable Interventional

Adjunctive Treatment With Vitamin D3 in Patients With Active IBD

NCT04225819
View directory record Official record
Conditions
IBD, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Vitamin D3 Deficiency
Interventions
Vitamin D3, Placebo
Dietary Supplement · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 23, 2026, 4:46 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

NCT00389519
View directory record Official record
Conditions
Hypertension
Interventions
ramipril, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 16 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
39
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 23, 2026, 4:46 AM EDT